<DOC>
	<DOCNO>NCT02015260</DOCNO>
	<brief_summary>Objective To assess efficacy topical application Nitric Oxide , deliver use acidify nitrite . Design Multicentre , randomize , control , dose range trial . A control arm three dos acidify nitrite apply topically 12 week 12 week follow . Setting The trial set European genitourinary medicine clinic Participants Male female volunteer 18 year age 2 50 ano-genital wart , 328 screen eligibility 299 subject 40 centre randomise . Exclusions Pregnancy ; concomitant Sexually Transmitted Disease ; internal wart require treatment surgery /laser ; diabetes ; Human Immunodeficiency Virus-positive , immunosuppressed and/or use immunosuppressive therapy ; drug abuse . intervention compare - Control Placebo nitrite cream placebo citric acid cream twice daily - A ) 3 % sodium nitrite + 4.5 % citric acid cream twice daily - B ) 6 % sodium nitrite + 9 % citric acid cream daily - C ) 6 % sodium nitrite + 9 % citric acid cream twice daily Outcomes - Primary proportion patient complete clearance target wart Secondary - Time clearance - Wart area - Wart count - Patient investigator assessment efficacy - Safety - Tolerability - Adherence</brief_summary>
	<brief_title>A Trial Efficacy Safety Topical Nitric Oxide Patients With Anogenital Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Males females 18 year age 250 wart anogenital region . Female patient childbearing potential willing use nonbarrier method contraception entry duration study . patient willing use barrier protection duration study . All patient able comply requirement protocol likely return followup visit contactable duration study . Patients clinically relevant abnormal haematology biochemistry result ( determined sample take Visit 1 ) . Patients use active therapy anogenital wart within 2 week randomisation study drug , i.e . Visit 2 . Patients use local supportive medication , include topical corticosteroid betainterferon , within 2 week study entry . Patients used medication know adversely affect haematology profile , include local anaesthetic ( benzocaine , lidocaine , etc ) , nitrofurantoin , sulphonylureas sulphonamides within 2 week study entry . [ Word 'adversely ' add Protocol Amendment 2 , 7 May 2002 . ] Patients abnormal anogenital skin , eczema , skin heal follow surgery ( cryosurgery , laser ablation similar ) . Patients know concomitant sexually transmitted disease inhibit accurate assessment wart . Patients require treatment surgery laser internal wart . Male patient intraurethral wart [ delete Protocol Amendment 2 , 7 May 2002 ] . Patients diabetes ( Type I Type II diabetes ) . Patients know HIVpositive . Patients know immunosuppressed and/or use immunosuppressive therapy . Patients know abuse alcohol and/or drug history chronic alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>human papilloma virus infection</keyword>
	<keyword>Anogenital wart</keyword>
	<keyword>condylomata acuminata</keyword>
</DOC>